Wells Fargo has revised its stock price target for Metagenomi, reflecting changes made to its financial modeling. This adjustment comes as part of the bank's ongoing analysis of the biotechnology sector and the specific performance metrics of Metagenomi. The updated target is intended to provide investors with a more accurate assessment of the company's market position and potential future performance.
Related Articles
Don't miss out on breaking stories and in-depth articles.